Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting. Methods: The medical records of 67 patients with BD prescribed ADA between January 2012 and December 2020 at five referral centers in Korea were retrospectively analyzed and the safety and efficacy of ADA within 52 weeks were assessed. To evaluate the clinical efficacy of ADA, the Disease Activity Index for Intestinal BD (DAIBD) and representative blood biochemical markers were compared at 0, 12, 24, and 52 weeks of ADA treatment. Results: During the follow-up period of 52 weeks, 46 patients continued ADA treatment. The cumulative drug survival rate was 83.5%. The DAIBD score decreased over the study period (p < 0.001). Moreover, the erythrocyte sedimentation rate, serum C-reactive protein levels, and serum albumin levels significantly improved at 12, 24, and 52 weeks of ADA treatment (all, p <0.05). Conclusions: As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD.
Abstract
Background/Aims: The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting. Methods: The medical records of 67 patients with BD prescribed ADA between January 2012 and December 2020 at five referral centers in Korea were retrospectively analyzed and the safety and efficacy of ADA within 52 weeks were assessed. To evaluate the clinical efficacy of ADA, the Disease Activity Index for Intestinal BD (DAIBD) and representative blood biochemical markers were compared at 0, 12, 24, and 52 weeks of ADA treatment. Results: During the follow-up period of 52 weeks, 46 patients continued ADA treatment. The cumulative drug survival rate was 83.5%. The DAIBD score decreased over the study period (p < 0.001). Moreover, the erythrocyte sedimentation rate, serum C-reactive protein levels, and serum albumin levels significantly improved at 12, 24, and 52 weeks of ADA treatment (all, p <0.05). Conclusions: As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD.
참고문헌 (29)
- Greco A, "Behçet’s disease : new insights into pathophysiology, clinical features and treatment options", Autoimmun Rev, 17, pp.567~575 (2018)
- 조성빈, "New Insights in the Clinical Understanding of Behçet’s Disease", Yonsei Medical Journal, 53(1), pp.35~42 (2012), 연세대학교의과대학
- Sakane T, "Behçet’s disease", N Engl J Med, 341, pp.1284~1291 (1999)
- Yong Eun Park, "Updated treatment strategies for intestinal Behçet’s disease", The Korean Journal of Internal Medicine, 33(1), pp.1~19 (2018), 대한내과학회[DOI]
- Hisamatsu T, "Diagnosis and management of intestinal Behçet’s disease", Clin J Gastroenterol, 7, pp.205~212 (2014)
- Evereklioglu C, "Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease", Mediators Inflamm, 11, pp.87~93 (2002)
- Hassard PV, "Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease : a case report", Gastroenterology, 120, pp.995~999 (2001)
- Byeon JS, "Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet’s disease : report of a case", Dis Colon Rectum, 50, pp.672~676 (2007)
- Ju JH, "Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab : rapid healing of Behçet’s ulcer with infliximab", Clin Rheumatol, 26, pp.1383~1385 (2007)
- Iwata S, "Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet’s disease", Rheumatology(Oxford), 48, pp.1012~1013 (2009)
- Ariyachaipanich A, "Intestinal Behçet’s disease : maintenance of remission with adalimumab monotherapy", Inflamm Bowel Dis, 15, pp.1769~1771 (2009)
- Hisamatsu T, "The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease : indication of anti-TNFα monoclonal antibodies", J Gastroenterol, 49, pp.156~162 (2014)
- Tanida S, "Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease", Clin Gastroenterol Hepatol, 13, pp.940~948 (2015)
- Sugimura N, "Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet’s disease", Dig Liver Dis, 51, pp.967~971 (2019)
- Yasuo Suzuki, "Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study", Intestinal research, 19(3), pp.301~312 (2021), 대한장연구학회[DOI]
- 박지혜, "Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease", Gut and Liver, 12(6), pp.623~632 (2018), 거트앤리버 소화기연관학회협의회
- Cheon JH, "Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s disease", Inflamm Bowel Dis, 17, pp.605~613 (2011)
- Tadakazu Hisamatsu, "Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study", Intestinal research, 19(4), pp.408~418 (2021), 대한장연구학회[DOI]
- Lee JH, "Efficacy of infliximab in intestinal Behçet’s disease : a Korean multicenter retrospective study", Inflamm Bowel Dis, 19, pp.1833~1838 (2013)
- Zhang Z, "Risk of tuberculosis in patients treated with TNF-α antagonists : a systematic review and meta-analysis of randomised controlled trials", BMJ Open, 7, pp.e012567~ (2017)
- 신승용, "Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study", Intestinal research, 20(3), pp.350~360 (2022), 대한장연구학회[DOI]
- Burmester GR, "Adalimumab : long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease", Ann Rheum Dis, 72, pp.517~524 (2013)
- Sandborn WJ, "Adalimumab for maintenance treatment of Crohn’s disease : results of the CLASSIC II trial", Gut, 56, pp.1232~1239 (2007)
- Watanabe M, "Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease", J Crohns Colitis, 6, pp.160~173 (2012)
- Kawabata H, "Myelodysplastic syndrome complicated with inflammatory intestinal ulcers : significance of trisomy 8", Intern Med, 45, pp.1309~1314 (2006)
- Ahn JK, "Behcet’s disease associated with malignancy in Korea : a single center experience", Rheumatol Int, 30, pp.831~835 (2010)
- Lin Y, "Behcet’s disease associated with malignancy : a report of 41 Chinese cases", Int J Rheum Dis, 17, pp.459~465 (2014)
- Yuki Mori, "Long-term outcome after surgery in a patient with intestinal Behçet’s disease complicated by myelodysplastic syndrome and trisomy 8", Intestinal research, 18(4), pp.469~475 (2020), 대한장연구학회[DOI]
- Shen Y, "High Incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Behçet’s disease associated with myelodysplastic syndrome : a series of 16 consecutive chinese patients from the Shanghai Behçet’s disease database and comparison with the literature", Biomed Res Int, 2018, pp.8535091~ (2018)